ArticleeLife2020
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.The Journal of clinical investigation · 2021Trial
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Walking the tightrope: Balancing immune checkpoints and their inhibitors in host defence against bacterial infections.Journal of applied biomedicine · 2026Review
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- A co-evolutionary perspective on humans andeLife · 2026Review
- Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Frontiers in immunology · 2026Review
- Factors Associated with Active Tuberculosis Disease in Patients with Lung Cancer Following Immune Checkpoint Blockade Therapy: A Retrospective Cohort Study and Case Reports.Infection and drug resistance · 2026Article
- AFrontiers in tuberculosis · 2026Article
- NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses.Frontiers in immunology · 2026Review
- T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.Journal of internal medicine · 2026Review
- Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.Frontiers in immunology · 2026Review
- Multiparameter antigen-specific immunoprofiling in subjects with negative IGRA and TST results with potentialFrontiers in cellular and infection microbiology · 2026Article
- Human alveolar macrophage function is impaired in tuberculosis contacts with diabetes.EBioMedicine · 2025Article
- Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages.Nature microbiology · 2025Article
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- Microbial Clearance of RefractoryPharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors.Cancer innovation · 2025Article
- A pharmacovigilance analysis of post-marketing safety of durvalumab.Scientific reports · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Liku B TezeraNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-7898-6709
Magdalena K BieleckaNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Paul OgongoAfrica Health Research Institute, KwaZulu Natal, South Africa.ORCID 0000-0002-0093-5768
Naomi F WalkerWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Matthew EllisNIHR Biomedical Research Centre, School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Diana J Garay-BaqueroNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-9450-8504
Kristian ThomasNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Michaela T ReichmannNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-6714-8400
David A JohnstonNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Katalin Andrea WilkinsonThe Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-9796-2040
Mohamed AhmedAfrica Health Research Institute, KwaZulu Natal, South Africa.
Sanjay JogaiNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Suwan N JayasingheBioPhysics Group, Department of Mechanical Engineering, University College London, London, United Kingdom.
Robert J WilkinsonThe Francis Crick Institute, London, United Kingdom.
Salah MansourNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-5982-734X
Gareth J ThomasNIHR Biomedical Research Centre, School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-3832-7335
Christian H OttensmeierNIHR Biomedical Research Centre, School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-3619-1657
Alasdair LeslieAfrica Health Research Institute, KwaZulu Natal, South Africa.
Paul T ElkingtonNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-0390-0613
NIHR Southampton Biomedical Research Centre · GBAfrica Health Research Institute · ZAThe Francis Crick Institute · GBInstitute of Primate Research · KEUniversity College London · GBUniversity of Cape Town · ZA
Funding
Validation and Application of a Model for Human-like TB Latency in RabbitsU19AI111276 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, ALLAND, DAVID · 2014 to 2020
$23.3MBill and Melinda Gates Foundation OPP1137006Cancer Research UK 23562Cancer Research UK FC0010218Medical Research Council MR/N006631/1Medical Research Council MR/P023754/1Medical Research Council MR/S024220/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001039/1NIAID NIH HHS U19 AI111276NIH HHS U19AI111276UK Research and Innovation FC0010218Wellcome Trust 104803Wellcome Trust 203135Wellcome Trust 210662/Z/18/ZWellcome Trust FC0010218Wessex Medical Research 2017
Abstract
Previously, we developed a 3-dimensional cell culture model of human tuberculosis (TB) and demonstrated its potential to interrogate the host-pathogen interaction (Tezera et al., 2017a). Here, we use the model to investigate mechanisms whereby immune checkpoint therapy for cancer paradoxically activates TB infection. In patients, PD-1 is expressed in
Indexed as
CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell HypoxiaGranulomaHumansImmunotherapyLatent TuberculosisMicrospheresMycobacterium tuberculosisProgrammed Cell Death 1 ReceptorTumor Necrosis Factor-alphaUp-RegulationPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTumor Necrosis Factor-alphahost-pathogen interactionhumanimmune checkpoint inhibitorsimmunologyinflammationpathologyTNFtuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.